Vitaherpavac

a dry inactivated herpes simplex virus culture vaccine obtained by using the Vero B continuous cell line as a substrate for accumulation of herpes simplex virus types 1 (US strain) and 2 (VN strain)

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barinskiĭ, I F: 2 articles (01/2010 - 09/2009)
2.	Makhmudov, F R: 1 article (01/2010)
3.	Barkhaleva, O A: 1 article (09/2009)
4.	Khorosheva, T V: 1 article (09/2009)
5.	Ladyzhenskaia, I P: 1 article (09/2009)
6.	Mikhaĭlova, G R: 1 article (09/2009)
7.	Podcherniaeva, R Ia: 1 article (09/2009)
8.	Shalunova, N V: 1 article (09/2009)
9.	Vorob'eva, M S: 1 article (09/2009)

Related Diseases

1.	Infections 09/01/2009 - "The trials have yielded positive results that suggest that it is expedient to introduce of the new vaccine Vitaherpavac into practice to treat chronic recurrent herpetic infection of various localizations. "
2.	Viremia 01/01/2010 - "Prevention of recurrent genital herpes with the inactivated herpetic divaccine Vitaherpavac against herpes simplex virus types 1 and 2 has a number of advantages over the most commonly used symptomatic therapy: it ceases or significantly reduces the number of recurrences and accordingly prolongs a relapse-free interval, abolishes viremia and the manifestations of clinical symptoms of recurrences, induces no dependence to the vaccine. "
3.	Herpes Genitalis (Genital Herpes) 01/01/2010 - "Prevention of recurrent genital herpes with the inactivated herpetic divaccine Vitaherpavac against herpes simplex virus types 1 and 2 has a number of advantages over the most commonly used symptomatic therapy: it ceases or significantly reduces the number of recurrences and accordingly prolongs a relapse-free interval, abolishes viremia and the manifestations of clinical symptoms of recurrences, induces no dependence to the vaccine. "

Related Drugs and Biologics

1.	Vaccines

Related Therapies and Procedures

1.	Therapeutics